1. Home
  2. GFR vs LBRX Comparison

GFR vs LBRX Comparison

Compare GFR & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Greenfire Resources Ltd.

GFR

Greenfire Resources Ltd.

HOLD

Current Price

$5.78

Market Cap

655.9M

Sector

N/A

ML Signal

HOLD

LBRX

LB Pharmaceuticals Inc

N/A

Current Price

$23.34

Market Cap

602.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GFR
LBRX
Founded
2018
2015
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
655.9M
602.6M
IPO Year
N/A
2025

Fundamental Metrics

Financial Performance
Metric
GFR
LBRX
Price
$5.78
$23.34
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$49.00
AVG Volume (30 Days)
73.6K
180.8K
Earning Date
03-13-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
252.40
N/A
EPS
1.37
N/A
Revenue
$470,838,329.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$4.21
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.81
$13.36
52 Week High
$6.67
$24.95

Technical Indicators

Market Signals
Indicator
GFR
LBRX
Relative Strength Index (RSI) 59.17 55.09
Support Level $5.66 $23.52
Resistance Level $6.12 $24.84
Average True Range (ATR) 0.28 1.52
MACD 0.02 0.09
Stochastic Oscillator 66.67 64.14

Price Performance

Historical Comparison
GFR
LBRX

About GFR Greenfire Resources Ltd.

Greenfire Resources Ltd explores, acquires, develops and produces oil and gas in the Canadian energy sector and internationally. Greenfire currently has two producing oil sand assets, Hangingstone Expansion and Hangingstone Demo. The Company has one reportable operating segment which is made up of its oil sands operations based on geographic location : Athabasca oil sands region of Alberta, Canada, nature of the products sold and integration of facilities and operations.

About LBRX LB Pharmaceuticals Inc

LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.

Share on Social Networks: